| Name | Title | Contact Details |
|---|---|---|
Joseph Spagnardi |
Executive Vice President of Legal and Compliance | Profile |
Ting Chen |
Senior Vice President - US Regulatory Affairs | Profile |
Andrew Zoltan |
Vice President, Intellectual Property and Litigation | Profile |
Gregory Montalbano |
Corporate Counsel and Data Privacy Officer | Profile |
Blue Earth Diagnostics (BED) is a privately held diagnostics company focused on the development and commercialisation of molecular imaging technologies.
Vetagro is a company that specializes in feed additive development and production for the animal feed industry. They focus on developing targeted solutions through scientific research, technological development, innovative formulation, and a focus on q...
Solesis is an innovative provider of biomaterials solutions and services primarily focused on the medical device and advanced therapy industries.
Blue Sky Broadcast is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.